Platelets, coagulation and fibrinolysis in breast cancer progression

Breast Cancer Research

Volumn 15, Issue 4, 2013, Pages

  Lal, Inder ^a   Dittus, Kim ^a   Holmes, Chris E ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; CD40 LIGAND; COLONY STIMULATING FACTOR 1; ENDOSTATIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBRINOGEN RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBRONECTIN; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; METALLOPROTEINASE; PADGEM PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; PROTEIN P53; PROTEINASE ACTIVATED RECEPTOR 2; SOMATOMEDIN; THROMBOCYTE FACTOR 4; THROMBOPLASTIN; THROMBOSPONDIN 1; THROMBOXANE A2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UVOMORULIN; VASCULOTROPIN; VASCULOTROPIN A; VITRONECTIN RECEPTOR; ANTICOAGULANT AGENT;

ANGIOGENESIS; APOPTOSIS; BLOOD CLOTTING; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CELL ADHESION; CELL DEATH; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CELL TRANSFORMATION; CHEMOTAXIS; CIRCULATING TUMOR CELL; EXTRACELLULAR MATRIX; EXTRAVASATION; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INTRACELLULAR SIGNALING; META ANALYSIS (TOPIC); METASTASIS; NONHUMAN; PROTEIN PHOSPHORYLATION; RECURRENCE FREE SURVIVAL; REVIEW; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; VENOUS THROMBOEMBOLISM; BLOOD; BREAST NEOPLASMS; DISEASE COURSE; DRUG EFFECTS; FEMALE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD PLATELETS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PLATELET ACTIVATION;

EID: 84881018482     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3425     Document Type: Review

References (87)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 10.1016/j.cell.2011.02.013, 21376230.
2. Chew HK, Wun T, Harvey DJ, Zhou H, White RH. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 2007, 25:70-76.
3. Caine GJ, Stonelake PS, Rea D, Lip GY. Coagulopathic complications in breast cancer. Cancer 2003, 98:1578-1586. 10.1002/cncr.11702, 14534872.
4. Caine GJ, Lip GY, Stonelake PS, Ryan P, Blann AD. Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma. Thromb Haemost 2004, 92:185-190.
5. Ferriere JP, Bernard D, Legros M, Chassagne J, Chollet P, Gaillard G, Plagne R. beta-Thromboglobulin in patients with breast cancer. Am J Hematol 1985, 19:47-53. 10.1002/ajh.2830190107, 2580432.
6. Alonso-Escolano D, Strongin AY, Chung AW, Deryugina EI, Radomski MW. Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins. Br J Pharmacol 2004, 141:241-252. 10.1038/sj.bjp.0705606, 1574193, 14691052.
7. Taucher S, Salat A, Gnant M, Kwasny W, Mlineritsch B, Menzel RC, Schmid M, Smola MG, Stierer M, Tausch C, Galid A, Steger G, Jakesz R, Austrian Breast and Colorectal Cancer Study Group Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost 2003, 89:1098-1106. Austrian Breast and Colorectal Cancer Study Group.
8. Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semin Thromb Hemost 2004, 30:95-108.
9. Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost 2011, 9:237-249. 10.1111/j.1538-7836.2010.04131.x, 21040448.
10. Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost 2011, 105(Suppl 1):S13-33.
11. Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 1968, 61:46-52. 10.1073/pnas.61.1.46, 285903, 5246932.
12. Placke T, Orgel M, Schaller M, Jung G, Rammensee HG, Kopp HG, Salih HR. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res 2012, 72:440-448. 10.1158/0008-5472.CAN-11-1872, 22127925.
13. Karpatkin S, Ambrogio C, Pearlstein E. The role of tumor-induced platelet aggregation, platelet adhesion and adhesive proteins in tumor metastasis. Prog Clin Biol Res 1988, 283:585-606.
14. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 2011, 20:576-590. 10.1016/j.ccr.2011.09.009, 3487108, 22094253.
15. Boucharaba A, Guillet B, Menaa F, Hneino M, van Wijnen AJ, Clezardin P, Peyruchaud O. Bioactive lipids lysophosphatidic acid and sphingosine 1-phosphate mediate breast cancer cell biological functions through distinct mechanisms. Oncol Res 2009, 18:173-184. 10.3727/096504009790217399, 20112503.
16. Caine GJ, Lip GY, Blann AD. Platelet-derived VEGF, Flt-1, angiopoietin-1 and P-selectin in breast and prostate cancer: further evidence for a role of platelets in tumour angiogenesis. Ann Med 2004, 36:273-277. 10.1080/07853890410026098, 15224653.
17. Kuznetsov HS, Marsh T, Markens BA, Castaño Z, Greene-Colozzi A, Hay SA, Brown VE, Richardson AL, Signoretti S, Battinelli EM, McAllister SS. Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells. Cancer Discov 2012, 2:1150-1165. 10.1158/2159-8290.CD-12-0216, 22896036.
18. Alonso-Escolano D, Medina C, Cieslik K, Radomski A, Jurasz P, Santos-Martinez MJ, Jiffar T, Ruvolo P, Radomski MW. Protein kinase C delta mediates platelet-induced breast cancer cell invasion. J Pharmacol Exp Ther 2006, 318:373-380. 10.1124/jpet.106.103358, 16617167.
19. Oleksowicz L, Mrowiec Z, Schwartz E, Khorshidi M, Dutcher JP, Puszkin E. Characterization of tumor-induced platelet aggregation: the role of immunorelated GPIb and GPIIb/IIIa expression by MCF-7 breast cancer cells. Thromb Res 1995, 79:261-274. 10.1016/0049-3848(95)00113-6, 8533122.
20. Pacchiarini L, Zucchella M, Milanesi G, Tacconi F, Bonomi E, Canevari A, Grignani G. Thromboxane production by platelets during tumor cell-induced platelet activation. Invasion Metastasis 1991, 11:102-109.
21. Grignani G, Pacchiarini L, Ricetti MM, Dionigi P, Jemos V, Zucchella M, Fratino P. Mechanisms of platelet activation by cultured human cancer cells and cells freshly isolated from tumor tissues. Invasion Metastasis 1989, 9:298-309.
22. Felding-Habermann B, O'Toole TE, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH, Hughes PE, Pampori N, Shattil SJ, Saven A, Mueller BM. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci USA 2001, 98:1853-1858. 10.1073/pnas.98.4.1853, 29346, 11172040.
23. Battinelli EM, Markens BA, Italiano JE. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood 2011, 118:1359-1369. 10.1182/blood-2011-02-334524, 3152500, 21680800.
24. Tokyol C, Ersoz G, Dilek FH, Gencer E, Kosar MN, Dilek ON. Thrombospondin 1 expression and angiogenesis in breast carcinoma and their relation with platelet activity. Ups J Med Sci 2009, 114:108-115. 10.1080/03009730902761797, 2852760, 19396698.
25. Janowska-Wieczorek A, Marquez-Curtis LA, Wysoczynski M, Ratajczak MZ. Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells. Transfusion 2006, 46:1199-1209. 10.1111/j.1537-2995.2006.00871.x, 16836568.
26. Kopp HG, Placke T, Salih HR. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res 2009, 69:7775-7783. 10.1158/0008-5472.CAN-09-2123, 19738039.
27. Drabsch Y, ten Dijke P. TGF-beta signaling in breast cancer cell invasion and bone metastasis. J Mammary Gland Biol Neoplasia 2011, 16:97-108. 10.1007/s10911-011-9217-1, 3095797, 21494783.
28. Coupland LA, Chong BH, Parish CR. Platelets and P-selectin control tumor cell metastasis in an organ-specific manner and independently of NK cells. Cancer Res 2012, 72:4662-4671. 10.1158/0008-5472.CAN-11-4010, 22836751.
29. Stubke K, Wicklein D, Herich L, Schumacher U, Nehmann N. Selectin-deficiency reduces the number of spontaneous metastases in a xenograft model of human breast cancer. Cancer Lett 2012, 321:89-99. 10.1016/j.canlet.2012.02.019, 22366582.
30. Mazouni C, Arun B, Andre F, Ayers M, Krishnamurthy S, Wang B, Hortobagyi GN, Buzdar AU, Pusztai L. Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. Br J Cancer 2008, 99:68-71. 10.1038/sj.bjc.6604443, 2453019, 18560403.
31. Brooks SA, Lomax-Browne HJ, Carter TM, Kinch CE, Hall DM. Molecular interactions in cancer cell metastasis. Acta Histochem 2010, 112:3-25. 10.1016/j.acthis.2008.11.022, 19162308.
32. Cooney CA, Jousheghany F, Yao-Borengasser A, Phanavanh B, Gomes T, Kieber-Emmons AM, Siegel ER, Suva LJ, Ferrone S, Kieber-Emmons T, Monzavi-Karbassi B. Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells. Breast Cancer Res 2011, 13:R58. 10.1186/bcr2895, 3218947, 21658254.
33. Liapis H, Flath A, Kitazawa S. Integrin alpha V beta 3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol 1996, 5:127-135. 10.1097/00019606-199606000-00008, 8727100.
34. Belloc C, Lu H, Soria C, Fridman R, Legrand Y, Menashi S. The effect of platelets on invasiveness and protease production of human mammary tumor cells. Int J Cancer 1995, 60:413-417. 10.1002/ijc.2910600324, 7829253.
35. Bambace NM, Levis JE, Holmes CE. The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets. Platelets 2010, 21:85-93. 10.3109/09537100903470298, 20063989.
36. Peterson JE, Zurakowski D, Italiano JE, Michel LV, Fox L, Klement GL, Folkman J. Normal ranges of angiogenesis regulatory proteins in human platelets. Am J Hematol 2010, 85:487-493. 10.1002/ajh.21732, 20575035.
37. Holmes CE, Huang JC, Pace TR, Howard AB, Muss HB. Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer. Clin Cancer Res 2008, 14:3070-3076. 10.1158/1078-0432.CCR-07-4640, 18483373.
38. Italiano JE, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, Ryeom S, Folkman J, Klement GL. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008, 111:1227-1233. 2214735, 17962514.
39. Ho-Tin-Noe B, Carbo C, Demers M, Cifuni SM, Goerge T, Wagner DD. Innate immune cells induce hemorrhage in tumors during thrombocytopenia. Am J Pathol 2009, 175:1699-1708. 10.2353/ajpath.2009.090460, 2751565, 19729481.
40. Demers M, Ho-Tin-Noe B, Schatzberg D, Yang JJ, Wagner DD. Increased efficacy of breast cancer chemotherapy in thrombocytopenic mice. Cancer Res 2011, 71:1540-1549. 10.1158/0008-5472.CAN-10-2038, 3078642, 21212409.
41. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol 2010, 28:1467-1472. 10.1200/JCO.2009.22.7918, 2849768, 20159825.
42. Takkouche B, Regueira-Mendez C, Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 2008, 100:1439-1447. 10.1093/jnci/djn324, 18840819.
43. Harker LA, Kadatz RA. Mechanism of action of dipyridamole. Thromb Res Suppl 1983, 4:39-46.
44. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012, 379:1591-1601. 10.1016/S0140-6736(12)60209-8, 22440947.
45. van den Berg YW, Osanto S, Reitsma PH, Versteeg HH. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood 2012, 119:924-932. 10.1182/blood-2011-06-317685, 22065595.
46. Bluff JE, Brown NJ, Reed MW, Staton CA. Tissue factor, angiogenesis and tumour progression. Breast Cancer Res 2008, 10:204. 10.1186/bcr1871, 2397518, 18373885.
47. Ueno T, Toi M, Koike M, Nakamura S, Tominaga T. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer 2000, 83:164-170. 2363475, 10901365.
48. Hu C, Huang L, Gest C, Xi X, Janin A, Soria C, Li H, Lu H. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells. J Hematol Oncol 2012, 5:16. 10.1186/1756-8722-5-16, 3394220, 22534171.
49. Ryden L, Grabau D, Schaffner F, Jonsson PE, Ruf W, Belting M. Evidence for tissue factor phosphorylation and its correlation with protease-activated receptor expression and the prognosis of primary breast cancer. Int J Cancer 2010, 126:2330-2340. 2847028, 19795460.
50. Vrana JA, Stang MT, Grande JP, Getz MJ. Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: paracrine regulation by carcinoma cell-derived members of the transforming growth factor beta family. Cancer Res 1996, 56:5063-5070.
51. Albrektsen T, Sorensen BB, Hjorto GM, Fleckner J, Rao LV, Petersen LC. Transcriptional program induced by factor VIIa-tissue factor, PAR1 and PAR2 in MDA-MB-231 cells. J Thromb Haemost 2007, 5:1588-1597. 10.1111/j.1538-7836.2007.02603.x, 2831055, 17470200.
52. Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC, Furie B. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009, 15:6830-6840. 10.1158/1078-0432.CCR-09-0371, 2783253, 19861441.
53. Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis?. J Thromb Haemost 2007, 5:520-527. 10.1111/j.1538-7836.2007.02369.x, 17166244.
54. Versteeg HH, Schaffner F, Kerver M, Petersen HH, Ahamed J, Felding-Habermann B, Takada Y, Mueller BM, Ruf W. Inhibition of tissue factor signaling suppresses tumor growth. Blood 2008, 111:190-199. 10.1182/blood-2007-07-101048, 2200804, 17901245.
55. Cole M, Bromberg M. Tissue factor as a novel target for treatment of breast cancer. Oncologist 2013, 18:14-18. 10.1634/theoncologist.2012-0322, 23287882.
56. Marchetti M, Russo L, Balducci D, Falanga A. All trans-retinoic acid modulates the procoagulant activity of human breast cancer cells. Thromb Res 2011, 128:368-374. 10.1016/j.thromres.2011.03.006, 21458031.
57. Falanga A, Toma S, Marchetti M, Palumbo R, Raffo P, Consonni R, Marziali S, Dastoli G, Barbui T. Effect of all-trans-retinoic acid on the hypercoagulable state of patients with breast cancer. Am J Hematol 2002, 70:9-15. 10.1002/ajh.10073, 11994976.
58. Shoji M, Sun A, Kisiel W, Lu YJ, Shim H, McCarey BE, Nichols C, Parker ET, Pohl J, Mosley CA, Alizadeh AR, Liotta DC, Snyder JP. Targeting tissue factor-expressing tumor angiogenesis and tumors with EF24 conjugated to factor VIIa. J Drug Target 2008, 16:185-197. 10.1080/10611860801890093, 18365880.
59. Yu JL, Xing R, Milsom C, Rak J. Modulation of the oncogene-dependent tissue factor expression by kinase suppressor of ras 1. Thromb Res 2010, 126:e6-10. 10.1016/j.thromres.2010.04.014, 20553947.
60. Zhang X, Yu H, Lou JR, Zheng J, Zhu H, Popescu NI, Lupu F, Lind SE, Ding WQ. MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells. J Biol Chem 2011, 286:1429-1435. 10.1074/jbc.M110.146530, 3020751, 21059650.
61. Koizume S, Jin MS, Miyagi E, Hirahara F, Nakamura Y, Piao JH, Asai A, Yoshida A, Tsuchiya E, Ruf W, Miyagi Y. Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII. Cancer Res 2006, 66:9453-9460. 10.1158/0008-5472.CAN-06-1803, 17018600.
62. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996, 2:209-215. 10.1038/nm0296-209, 8574967.
63. Garnier D, Magnus N, D'Asti E, Hashemi M, Meehan B, Milsom C, Rak J. Genetic pathways linking hemostasis and cancer. Thromb Res 2012, 129(Suppl 1):S22-29.
64. Jiang X, Zhu S, Panetti TS, Bromberg ME. Formation of tissue factor-factor VIIa-factor Xa complex induces activation of the mTOR pathway which regulates migration of human breast cancer cells. Thromb Haemost 2008, 100:127-133.
65. Hjortoe GM, Petersen LC, Albrektsen T, Sorensen BB, Norby PL, Mandal SK, Pendurthi UR, Rao LV. Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood 2004, 103:3029-3037. 10.1182/blood-2003-10-3417, 2837482, 15070680.
66. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000, 407:258-264. 10.1038/35025229, 11001069.
67. Even-Ram S, Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, Ginzburg Y, Reich R, Vlodavsky I, Bar-Shavit R. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 1998, 4:909-914. 10.1038/nm0898-909, 9701242.
68. Hu L, Lee M, Campbell W, Perez-Soler R, Karpatkin S. Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood 2004, 104:2746-2751. 10.1182/blood-2004-03-1047, 15265791.
69. DeFeo K, Hayes C, Chernick M, Ryn JV, Gilmour SK. Use of dabigatran etexilate to reduce breast cancer progression. Cancer Biol Ther 2010, 10:1001-1008. 10.4161/cbt.10.10.13236, 20798593.
70. Caunt M, Hu L, Tang T, Brooks PC, Ibrahim S, Karpatkin S. Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis. Cancer Res 2006, 66:4125-4132. 10.1158/0008-5472.CAN-05-2570, 16618733.
71. Schaffner F, Versteeg HH, Schillert A, Yokota N, Petersen LC, Mueller BM, Ruf W. Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development. Blood 2010, 116:6106-6113. 10.1182/blood-2010-06-289314, 3031395, 20861457.
72. Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006, 10:355-362. 10.1016/j.ccr.2006.10.002, 17097558.
73. Rak J, Milsom C, May L, Klement P, Yu J. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost 2006, 32:54-70. 10.1055/s-2006-933341, 16479463.
74. Han B, Nakamura M, Mori I, Nakamura Y, Kakudo K. Urokinase-type plasminogen activator system and breast cancer (Review). Oncol Rep 2005, 14:105-112.
75. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brünner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broët P, Romain S, Daxenbichler G, Windbichler G, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002, 94:116-128. 10.1093/jnci/94.2.116, 11792750.
76. Wolff C, Malinowsky K, Berg D, Schragner K, Schuster T, Walch A, Bronger H, Hofier H, Becker KF. Signalling networks associated with urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in breast cancer tissues: new insights from protein microarray analysis. J Pathol 2011, 223:54-63. 10.1002/path.2791, 21125664.
77. Malinowsky K, Wolff C, Berg D, Schuster T, Walch A, Bronger H, Mannsperger H, Schmidt C, Korf U, Höfler H, Becker KF. uPA and PAI-1-Related Signaling Pathways Differ between Primary Breast Cancers and Lymph Node Metastases. Transl Oncol 2012, 5:98-104. 3323931, 22496926.
78. Hurst NJ, Najy AJ, Ustach CV, Movilla L, Kim HR. Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progression. Biochem J 2012, 441:909-918. 10.1042/BJ20111020, 3342761, 22035541.
79. Bajou K, Lewalle JM, Martinez CR, Soria C, Lu H, Noel A, Foidart JM. Human breast adenocarcinoma cell lines promote angiogenesis by providing cells with uPA-PAI-1 and by enhancing their expression. Int J Cancer 2002, 100:501-506. 10.1002/ijc.10487, 12124797.
80. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RC. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004, 22:1944-1948. 10.1200/JCO.2004.10.002, 15143088.
81. Sideras K, Schaefer PL, Okuno SH, Sloan JA, Kutteh L, Fitch TR, Dakhil SR, Levitt R, Alberts SR, Morton RF, Rowland KM, Novotny PJ, Loprinzi CL. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 2006, 81:758-767. 10.4065/81.6.758, 16770976.
82. Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, Prandoni P, Bos MM, Richel DJ, van Tienhoven G, Büller HR. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005, 23:2130-2135. 10.1200/JCO.2005.03.134, 15699479.
83. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M, PROTECHT Investigators Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009, 10:943-949. 10.1016/S1470-2045(09)70232-3, 19726226, PROTECHT Investigators.
84. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, Samosh M, Bramwell V, Pritchard KI, Stewart D, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994, 343:886-889. 10.1016/S0140-6736(94)90008-6, 7908358.
85. Golubkov VS, Strongin AY. Proteolysis-driven oncogenesis. Cell Cycle 2007, 6:147-150. 10.4161/cc.6.2.3706, 17245132.
86. Jiang X, Guo YL, Bromberg ME. Formation of tissue factor-factor VIIa-factor Xa complex prevents apoptosis in human breast cancer cells. Thromb Haemost 2006, 96:196-201.
87. Powles TJ, Dady PJ, Williams J, Easty GC, Coombes RC. Use of inhibitors of prostaglandin synthesis in patients with breast cancer. Adv Prostaglandin Thromboxane Res 1980, 6:511-516.